Physician profile
James Hixon
NPI 1356340020
$4,086.76
in general payments reported to CMS, 2019-2025
26 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $300 · 2021: $652 · 2022: $581 · 2023: $319 · 2024: $413 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,124.11 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $819.66 | 2019-2024 | Xifaxan |
| Abbvie INC. | $508.52 | 2019-2025 | |
| Pfizer INC. | $342.12 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $304.68 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $296.40 | 2020-2025 | Tremfya |
| Madrigal Pharmaceuticals | $285.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $269.20 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $260.03 | 2024-2025 | Voquezna |
| Conmed Corporation | $221.92 | 2025 | Conmed Generators, Conmed Biliary |
| Covidien LP | $118.22 | 2019 | |
| Merck Sharp & Dohme LLC | $114.78 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $77.64 | 2020-2023 | Linzess |
| Redhill Biopharma INC. | $71.41 | 2020-2023 | Aemcolo, Talicia, Movantik |
| Boston Scientific Corporation | $70.86 | 2019 | |
| Nestle Healthcare Nutrition INC. | $64.79 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $39.43 | 2025 | |
| Pentax of America, INC. | $36.05 | 2022-2025 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
| Novo Nordisk INC | $31.92 | 2025 | Wegovy |
| Genzyme Corporation | $29.10 | 2022 | |
| Qol Medical, LLC | $21.62 | 2025 | Sucraid |
| Astrazeneca Pharmaceuticals LP | $20.10 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $20.00 | 2024 | Iqirvo |
| Ambu INC. | $18.34 | 2022 | |
| Celgene Corporation | $17.15 | 2023 | |
| Adc Therapeutics America, INC. | $16.20 | 2025 | |
| Allergan, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.